September 22, 2015 – A subset of atopic dermatitis is associated with increased susceptibility to eczema herpeticum (ADEH+). We previously reported that common single nucleotide polymorphisms (SNPs) in the IFN-γ (IFNG) and IFN-γ receptor 1 (IFNGR1) genes were associated with the ADEH+ phenotype.
September 22, 2015 – Atopic dermatitis (or eczema) is a chronic inflammatory disorder associated with sleep disturbances and quality-of-life impairment. Sleep disturbances have been shown to cause headaches in childhood. However, an association between eczema and headaches is not well established.
September 21 – The National Eczema Association (NEA) has awarded Dr. Aaron Drucker, Assistant Professor, Department of Dermatology at Brown University, with the NEA Burden of Disease Research Audit grant, the findings of which will help to raise the profile of eczema as a serious disease, to deliver stronger, more united messages to insurers, medical providers and policy-makers on behalf of the eczema community.
Erase the stigma of eczema Our boys Dylan (4) and Dean (2) suffer from eczema. We constantly wonder if our sons will be bullied or teased about their skin, and worry about what that could do to their self esteem and confidence. Talking about Itching for a Cure and our walk team helps people understand […]
August 17, 2015 – The National Eczema Association (NEA) is pleased to share news about a potential new topical non-steroidal treatment for mild-to-moderate eczema that you, the National Eczema Association community, helped make possible.
August 4, 2015 – The oral Janus kinase inhibitor tofacitinib citrate may be beneficial in the treatment of moderate to severe AD.
August 3, 2015 – Probiotic supplementation in pregnancy and early infancy can prevent infantile eczema, according to a review and meta-analysis published online July 21 in Allergy.
July 20, 2015 – Early nutrition and adiposity have been linked to atopic dermatitis (AD) development.
July 20, 2015 – Researchers at Yale School of Medicine have successfully treated patients with moderate to severe eczema using a rheumatoid arthritis drug.
July 13, 2015 – Anacor Pharmaceuticals Announces Positive Top-Line Results From Two Phase 3 Pivotal Studies of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic Dermatitis.